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Abstract
Introduction. Although cardiac function appears normal in patients with cirrhosis at rest, cardiac function deteriorates in 
these patients under stress conditions. Decreased cardiac function against stress may be due to coronary microvascular 
dysfunction in these patients. In this study, we aimed to evaluate coronary microvascular dysfunction in patients with 
cirrhosis by measuring coronary flow reserve (CFR) by transthoracic echocardiography.
Materials and methods. Thirty-eight patients with cirrhosis and 32 healthy subjects (as control group) were examined. 
In addition to standard two-dimesional (2D) and Doppler echocardiography, coronary flow velocity was measured by 
pulsed-wave Doppler from the middle to the distal part of the left anterior descending artery at the beginning and after 
dipyridamole infusion in the hyperemic state. CFR was measured as the ratio of hyperemic peak diastolic flow rate to 
basal peak diastolic flow rate.
Results. CFR was significantly lower in the cirrhosis group than in the control group (2.01 ± 0.31 and 2.84 ± 0.62; 
p < 0.0001). Increasing age, increasing myocardial mass, high aspartate aminotransferase and alanine aminotransfe-
rase, low hemoglobin, high C-reactive protein, decreased cholesterol and platelet levels were found to be associated 
with the reduction in CFR. Among all these factors only, the hemoglobin level and age were independent determinants 
of impaired CFR.
Conclusions. Impaired CFR in patients with cirrhosis promotes coronary microvascular dysfunction. The coronary mic-
rovascular dysfunction can potentially contribute to the development of cirrhotic cardiomyopathy.
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Echocardiographic examination  
and evaluation of coronary flow reserve
Each patient underwent TTDE. Acuson Sequoia C256 
ultrasound machine (Mountain View, CA, USA) was used. 
All patients included in the study underwent standard 2D 
and Doppler echocardiography in accordance with stan-
dard echocardiography guidelines [8]. EF was calculated 
using the modified Simpson’s method. Myocardial perfor-
mance index (MPI) of LV were calculated using TDI of the 
mitral annulus. LV mass was measured using Devereux’s 
formula [9].
The distal part of the LAD coronary artery in the epicar-
dial part of the anterior wall of the heart was examined by 
modifying the apical 2-chamber image. Coronary flow ve-
locities were recorded from the middle distal part of LAD 
coronary artery by pulse Doppler wave. Coronary flow rate 
was measured in a typical biphasic flow pattern consisting 
of diastolic and systolic components. Hyperemia was indu-
ced by infusion of 0.56 mg/kg dipyridamole for 4 minutes. 
Coronary diastolic peak velocities (DPV) were measured at 
baseline and hyperemia (Figure 1). The highest 3 Doppler 
recordings were averaged for each measurement. CFR was 
calculated as the ratio of hyperemic to baseline DPV [10]. In 
many studies, CFR value ≥ 2 has been considered normal 
[11–13]. Normal cut-off value for CFR ≥ 2 accepted and 
patients were divided into two groups as group 1 (49 pa-
tients) with preserved CFR ≥ 2 and group 2 (21 patients) 
with impaired CFR < 2.
Statistical analyses
Normal distribution of continuous variables was controlled 
by the Shapiro-Wilk test. Student’s t test was used to 
compare the two groups with respect to the variables with 
normal distribution and homogeneous group variances. 
Mann Whitney U test was used for non-homogeneous va-
riables. The results were expressed as mean ± standard 
deviation and median value. Categorical variables were 
analyzed using Fisher Exact test. Stepwise multivariate 
logistic regression analysis was performed to investigate 
the effect of other variables on CFR. A p < 0.05 was consi-
dered statistically significant. The data set was evaluated 
using the SPSS program (Statistical Package for the Social 
Sciences, version 16; SSPS Inc., Chicago, Illinois).
Results
The clinical and laboratory variables of the two groups 
were compared in Table 1. There were no differences in 
age and sex between patients and controls. Serum total 
cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) cholesterol, triglycerides, hemoglobin 
and platelet levels were significantly lower and C-reactive 
protein (CRP), aspartate aminotransferase (AST), alanine 
Introduction
There are several structural and functional cardiovascu-
lar changes in end-stage liver disease and these cardiova-
scular changes are known as cirrhotic cardiomyopathy [1]. 
Cardiac function in cirrhotic cardiomyopathy appears nor-
mal at rest, but heart cannot give the expected response to 
stress. For example, ventricular inotropic and chronotropic 
response in patients with cirrhosis is impaired in physical 
exercise and ejection fraction (EF) of left ventricular (LV) is 
depressed during stress even if it is normal at rest [2, 3].
Coronary flow reserve (CFR) measured by transthoracic 
Doppler echocardiography (TTDE) evaluates microvascular 
myocardial function in the absence of epicardial coronary 
artery stenosis [4]. TTDE is a highly practical (easily appli-
cable at the bedside), non-invasive, easily reproducible 
and inexpensive method of assessing CFR without radia-
tion exposure. CFR measurement by TTDE was confirmed 
by positron emission tomography and Doppler wire measu-
rement methods used to evaluate CFR [5, 6]. In this study, 
we aimed to evaluate coronary microvascular dysfunction 




Thirty-eight cirrhotic patients (mean age 46 ± 10 years, 26 
male) diagnosed by either liver biopsy and/or laboratory, 
clinical and ultrasonography findings were included in the 
study. The control group of 32 healthy individuals of similar 
age and sex were included in the study group. The study pro-
tocol was in conformity with the Declaration of Helsinki and 
has been approved by the institutional ethics committee.
Criteria of the exclusion from the study were determi-
ned as coronary artery disease (CAD), diabetes mellitus, 
hypertension, severe heart valve disease, chronic heart 
failure, hypertrophic cardiomyopathy, rhythms other than 
sinus rhythm, renal dysfunction, thyroid disease, chronic 
obstructive pulmonary disease, pulmonary hypertension, 
cor pulmonale, and poor echocardiographic image quality.
Systolic blood pressure ≥ 140 mm Hg and/or diastolic 
blood pressure ≥ 90 mm Hg in at least two measurements 
or the use of any antihypertensive drug therapy was defined 
as hypertension in patients. Diabetes mellitus was defined 
as the use of active antidiabetic drugs or fasting plasma 
glucose levels higher than 126 mg/dL or glucose levels 
higher than 200 mg/dL in any measurement. 
The severity of cirrhosis was calculated based on the 
five clinical features of the patient: 1) total bilirubin level, 
2) prothrombin time, 3) serum albumin, 4) acid grade and 
5) hepatic encephalopathy grade. The total score of the 
patient was used to determine the Child-Pugh class [7].
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Figure 1. Upper illustrates the distal left anterior descending artery coronary flow by color Doppler and illustrates the corresponding pulsed 
wave Doppler of the coronary flow with diastolic dominance at hyperemia (A); display as (B) at rest. Note the increase in coronary flow 
velocities
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LDL — low-density lipoproteins; CRP — C-reactive protein; AST — aspartate aminotransferase; ALT — alanine aminotransferase
288
Folia Cardiologica 2020, vol. 15, no. 4
www.journals.viamedica.pl/folia_cardiologica
laboratory parameters, AST, ALT, CRP, total cholesterol, he-
moglobin and platelet values were found to be statistically 
different between group 1 and group 2. Beta-blocker and 
diuretic use were more frequent in group 2. Univariate logi-
stic regression analysis was performed in terms of parame-
ters affecting microvascular dysfunction and age, myocardial 
mass index, AST, ALT, hemoglobin, CRP, total cholesterol and 
platelet values were found to affect CFR (Table 5A). However, 
stepwise multivariate logistic regression analysis revealed 
that only hemoglobin and age were determinant for CFR. It 
was observed that the probability of CFR to be below 2 was 
increased 1.5 times for each unit of hemoglobin decrease 
and 1.1 times for each age increase (Table 5B).
Among patients with cirrhosis, the most frequent un-
derlying disease was hepatitis B infection (42.1%), cryp-
togenic cirrhosis (18.4%), hepatitis C infection (15.7%), 
alcohol (10.5%) primary sclerosing cholangitis (2.6%), ul-
cerative colitis (2.6%) and other causes (7.8%). Regarding 
the Child-Pugh Scoring for cirrhosis, 47.3% of the cirrhotic 
patients were stratified in the Child score B, 44.7% of the 
aminotransferase (ALT) levels were higher in patients with 
cirrhosis compared with the control group.
There were no significant differences with regard to 
ejection fraction; however, left ventricular wall thickness, 
left atrial diameter, left ventricular volumes and left ven-
tricular mass were higher in patients with cirrhosis com-
pared with the control group (Table 2). Additionally, MPI of 
LV were higher in patients with cirrhosis than in controls 
(0.28 ± 0.04 and 0.23 ± 0.05, p = 0.001).
The mean baseline peak systolic coronary flow veloci-
ty was also similar in both groups. However, baseline peak 
diastolic coronary flow velocity, hyperemic peak systolic co-
ronary flow velocity, hyperemic peak diastolic coronary flow 
velocity was significantly lower in patients with cirrhosis com-
pared with the control group (Table 3). CFR was significantly 
less in liver transplant candidates than in the control group 
(2.01 ± 0.31 and 2.84 ± 0.62; p < 0.0001). The groups in-
cluded in the study were compared in Table 4 for preserved 
and impaired CFR. Age and left ventricular mass were higher 
and hyperemic heart rate was lower in the group 2. Among 
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Table 4. The comparison of patients with impaired and preserved coronary flow reserve (CFR)
Parameter CFR ≥ 2 CFR < 2 p value
Age [y] 42.06 ± 11.73 48.71 ± 8.6 0.01
Gender [E] 29 (59%) 15 (71%) NS
Body surface area [m2] 1.84 ± 0.15 1.83 ± 0.21 NS
Basal heart rate [beats/min] 74 ± 12 73 ± 10 NS
Basal SBP [mm Hg] 114 ± 11 109 ± 10 NS
Hyperemic heart rate [beats/min] 92 ± 16 81 ± 11 0.01
Hyperemic SBP [mm Hg] 107 ± 10 105 ± 16 NS
LV mass index [g/m2] 93.85 ± 14.81 108.09 ± 18.29 0.003
Ejection fraction [%] 59.73 ±2.82 59.05 ± 2.50 NS
Glucose [mg/dL] 92.0 ± 12.1 97 ± 15.1 NS
Creatinine [mg/dL] 0.8 ± 0.2 0.7 ± 0.2 NS
AST [U/L] 38.1 ± 29.0 75.1 ± 62.3 0.004
ALT [U/L] 28.4 ± 21.8 43.1 ± 32.0 0.009
GGT [U/L] 44.40 ± 41.50 38.05 ± 24.36 NS
Hemoglobin [g/dL] 13.3 ± 2.4 11.4 ± 2.1 0.006
Platelets [× 10³/µL] 192.4 ± 102.6 123.0 ±70.1 0.01
Total cholesterol [mg/dL] 142.7 ± 42.6 115.4 ± 41.9 0.04
HDL cholesterol [mg/dL] 44.6 ± 6.6 34.7 ±16.1 NS
LDL cholesterol [mg/dL] 83.6 ± 34.4 66.1 ± 20.8 NS
Triglycerides [mg/dL] 96.6 ± 43.9 90.6 ± 65.5 NS
C-reactive protein [mg/L] 6.9 ± 10.8 15.0 ± 13.7 0.001
NS — non significant; SBP — systolic blood pressure; LV — left ventricle; AST — aspartate aminotransferase; ALT — alanine aminotransferase; GGT — gamma-glutamyl transferase; HDL — high-density lipoprote-
in; LDL — low-density lipoprotein
Table 5A. The determinants of impaired coronary flow reserve (CFR) according to the univariate logistic regression analysis
Parameter Risk ratio Confidence interval Beta p value
Age [y] 1.04 0.99–1.09 0.05 0.06
Myocardial mass index [g/m2] 1.05 1.01–1.09 0.05 0.01
AST [U/L] 1.02 1.01–1.04 0.02 0.01
ALT [U/L]) 1.02 0.90–1.04 0.02 0.07
Hemoglobin [g/dL] 1.40 1.09–1.79 –0.33 0.01
CRP [mg/L] 1.05 1.01–1.11 0.05 0.03
Total cholesterol [mg/dL] 1.01 1.01–1.03 –0.014 0.05
Platelets [× 10³/µL] 1.01 1.00–1.01 –0.007 0.01
AST — aspartate aminotransferase; ALT — alanine aminotransferase; CRP — C-reactive protein
Table 5B. Independent determinants for impaired coronary flow reserve (CFR) according to stepwise multivariate logistic regression ana-
lysis
Parameter Risk ratio Confidence interval Beta p value
Hemoglobin [g/dL] 1.5 1.07–2.11 –0.40 0.01
Age [year] 1.1 1.01–1.18 0.08 0.04
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patients were classified as Child score C and 7.8% of them 
were categorized in the child score A.
Dıscussıon
This study shows that CFR is impaired in patients with 
cirrhosis. This result supports coronary microvascular dys-
function in these patients. The inflammatory environment 
is likely to cause coronary microvascular dysfunction in 
patients with cirrhosis. Coronary microvascular dysfunction 
may play an important role in the pathogenesis of cirrhotic 
cardiomyopathy.
Cirrhotic cardiomyopathy is a clinical syndrome with ab-
normalities in the beta-adrenergic signaling pathway and 
cardiomyocyte plasma membrane and pathogenetic me-
chanisms in which vasodilator cytokine levels such as ni-
tric oxide are increased [14]. However, the role of coronary 
microvascular dysfunction in the development of cirrhosis 
cardiomyopathy is unknown. CFR demonstrates the ability 
of the microvascular system to react to a stimulus [15]. CFR 
is used to evaluate microvascular function [16, 17]. In our 
study, CFR was lower in patients with cirrhosis than in the 
control group. Decreased CFR is an important prognostic 
finding [17, 18]. It has been reported that impaired coro-
nary microvascular function is reversible in the absence of 
significant epicardial coronary stenosis [19].
We found that increasing age, increasing myocardial 
mass, high aspartate aminotransferase and alanine ami-
notransferase, low hemoglobin, high C-reactive protein, 
decreased cholesterol and platelet levels were found to 
be associated with the reduction in CFR. Among all the-
se factors, only the hemoglobin level and age were inde-
pendent determinants of impaired CFR. Increasing age 
is a well-known cause of decreased CFR [20], but in our 
study there was no age difference between the groups. In 
a previous study no alterations of CFR in anemia were fou-
nd [21]. Our study found a relationship between low hemo-
globin and impaired CFR. This highlights the role of anemia 
in the deterioration of cardiovascular function in patients 
with cirrhosis and may be a guide in the planning of tre-
atment. Our study showed that LV mass was increased in 
patients with cirrhosis and associated with decreased CFR. 
Previous studies have reported conflicting data on the ef-
fect of LV hypertrophy on CFR. In some publications, it has 
been reported that LV hypertrophy is a factor that decrea-
sed CFR [19], but not in others [22]. Our findings suggest 
that myocardial hypertrophy, which is involved in the me-
chanisms of cirrhotic cardiomyopathy, could be another 
factor playing a role in coronary microvascular function 
impairment. Studies have shown that there is a consistent 
association between the progression of cirrhosis and sy-
stolic and diastolic myocardial dysfunction [23, 24]. In our 
study, there was also a relation between decreased CFR 
and deterioration in liver function. That is, we found lower 
total cholesterol, lower thrombocyte, elevated AST and 
ALT associated with the decrease in CFR. Previous studies 
have shown an increase in CRP production in patients with 
cirrhosis [25]. In our study, we found that CRP levels were 
higher in patients with cirrhosis and CRP was associated 
with decreased CFR. This result suggests that increased 
inflammatory status in cirrhotic patients may contribute to 
the development of coronary microvascular dysfunction.
Earlier studies have shown that early stage atheroscle-
rosis reduces CFR [26]. In our study decreased CFR in pa-
tients with cirrhosis may be indicative of early stage athe-
rosclerosis. This conclusion suggests that further risk ad-
justment and more preventive treatment may be necessary 
to prevent CAD in cirrhotic patients.
Previous studies have shown that LVEF is normal at rest 
in the majority of patients with cirrhosis [24, 27]. In our 
study, we also found a similar EF in cirrhosis and control 
groups but the end-diastolic and end-systolic volumes were 
found to be higher in patients with cirrhosis, probably due to 
increased volume loading. Moreover, MPI of LV was higher 
in patients with cirrhosis than in controls. High MPI sup-
ports subclinical LV systolic dysfunction in these patients.
The study has some limitations. Our study had limited 
number of patients. We evaluated CFR noninvasively by TTE 
instead of using invasive measurements. CFR calculated 
by TTE has an excellent correlation with CFR calculated by 
positron emission tomography [5] and Doppler wires [28]. 
In our institutional experience also, noninvasive measure-
ment of CFR by TTE yielded very reproducible results as 
previously reported [29]. Another important restriction was 
not all patients underwent coronary angiography. Myocar-
dial perfusion scintigraphy was performed in 28 patients in 
the evaluation of cirrhosis patients before liver transplan-
tation. Coronary angiography was performed in 14 patients 
with abnormal myocardial perfusion scintigraphy (due to 
perfusion abnormality) and coronary angiographies of the-
se patients were normal.
Conclusion
In conclusion, decreased CFR values in patients with 
cirrhosis show the presence of coronary microvascular 
dysfunction. The coronary microvascular dysfunction can 
potentially contribute to the development of cirrhotic car-
diomyopathy. Clinical management of cirrhotic cardiomyo-
pathy remains uncertain because of lack of the clinical 
evidence and challenging diagnosis of the disease. There-
fore, we believe that CFR may be useful in early diagnosis 
of cirrhotic cardiomyopathy and may lead to a change in 
cirrhosis treatment.
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Streszczenie
Wstęp. Chociaż czynność serca u pacjentów z marskością wątroby oceniana w spoczynku wydaje się prawidłowa, to 
w warunkach wysiłku fizycznego lub obciążenia farmakologicznego ulega ona pogorszeniu. Zaburzenie czynności serca 
podczas obciążenia może być spowodowane dysfunkcją mikrokrążenia wieńcowego u tych chorych. Celem badania 
była ocena dysfunkcji mikrokrążenia wieńcowego u pacjentów z marskością wątroby przez pomiar rezerwy przepływu 
wieńcowego (CRF) za pomocą echokardiografii przezklatkowej.
Materiał i metody. Do badania włączono 38 chorych z marskością wątroby i 32 osoby zdrowe (grupa kontrolna). Oprócz 
standardowej echokardiografii dwuwymiarowej (2D) i echokardiografii doplerowskiej prędkość przepływu wieńcowego 
w odcinkach środkowym i dystalnym gałęzi przedniej lewej tętnicy zstępującej zmierzono za pomocą badania dople-
rowskiego metodą fali pulsacyjnej bezpośrednio przed wlewem dipirydamolu i po nim. Rezerwę przepływu wieńcowego 
mierzono jako stosunek maksymalnego przepływu rozkurczowego w obciążeniu do maksymalnego przepływu rozkur-
czowego w spoczynku.
Wyniki. Rezerwa przepływu wieńcowego była istotnie niższa w grupie z marskością wątroby niż w grupie kontrolnej (2,01 
± 0,31 i 2,84 ± 0,62; p < 0,0001). Stwierdzono, że ze zmniejszeniem CFR wiązały się: wiek, zwiększenie masy mięśnia 
sercowego, wysoka aktywność aminotransferaz asparaginianowej i alaninowej, niskie stężenie hemoglobiny, wysokie 
stężenie białka C-reaktywnego, obniżone stężenie cholesterolu i zmniejszona liczba płytek krwi. Jednak tylko stężenie 
hemoglobiny i wiek były niezależnymi determinantami zmniejszonej CFR.
Wnioski. Zmniejszenie CFR u chorych z marskością wątroby sprzyja dysfunkcji mikrokrążenia wieńcowego, która może 
prowadzić do rozwoju kardiomiopatii wątrobowej (marskiej).
Słowa kluczowe: echokardiografia, rezerwa przepływu wieńcowego, marskość
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